Trial Radar AI | ||
|---|---|---|
Clinical Trial NCT05009537 (CARTOGEN) for MDS, ALL, Other Hematologic Malignant Neoplasms is recruiting. See the Trial Radar Card View and AI discovery tools for all the details. Or ask anything here. | ||
One study matched filter criteria
Card View
Optical Genome Mapping in Hematological Malignancies (CARTOGEN) 200
Clinical Trial NCT05009537 (CARTOGEN) is an observational study for MDS, ALL, Other Hematologic Malignant Neoplasms that is recruiting. It started on 1 September 2021 with plans to enroll 200 participants. Led by University Hospital, Brest, it is expected to complete by 1 September 2026. The latest data from ClinicalTrials.gov was last updated on 17 August 2021.
Brief Summary
Establish the diagnostic potential of optical genome mapping in patients with suspected hematologic cancer
Official Title
Optical Genome Mapping in Hematological Malignancies
Conditions
MDSALLOther Hematologic Malignant NeoplasmsOther Study IDs
- CARTOGEN
- CARTOGEN - 29BRC21.0211
NCT ID Number
Start Date (Actual)
2021-09
Last Update Posted
2021-08-17
Completion Date (Estimated)
2026-09
Enrollment (Estimated)
200
Study Type
Observational
Status
Recruiting
Primary Outcome Measures
Secondary Outcome Measures
| Outcome Measure | Measure Description | Time Frame |
|---|---|---|
Establish the diagnostic potential of optical genome mapping in patients with suspected hematologic cancer | identification of anomalies by mapping identical to those identified by combining conventional cytogenetics and FISH. | 2021-2026 |
| Outcome Measure | Measure Description | Time Frame |
|---|---|---|
identification of new chromosomal abnormalities of clinical relevance. | 2021-2026 | |
identification of new chromosomal anomalies involved in oncogenic pathways | 2021-2026 |
Participation Assistant
Eligibility Criteria
Eligible Ages
Child, Adult, Older Adult
Eligible Sexes
All
- Minor/Major Patients
- Patients with suspected hemopathies for whom we receive a sample for diagnosis in the chromosomal genetics laboratory or for whom a diagnosis of hemopathy has already been made.
- No objection made or consent given
- Patients under judicial protection (guardianship, curatorship, ...),
- Refusal to participate
University Hospital, BrestStudy Central Contact
Contact: Marie-Bérengère, TROADEC, PhD, (33)230338055, [email protected]
Contact: Nathalie DOUET-GUILBERT, MD, PhD, (33)230338055, [email protected]
4 Study Locations in 1 Countries
CH Morlaix, service d'hémato clinique, Morlaix, France
Christophe NICOL, MD, Contact
Recruiting
CHIC, service d'hémato clinique, Quimper, France
Léanig LE CLEACH, MD, Contact
Recruiting
CH St Brieuc, service d'hémato clinique, Saint-Brieuc, France
Cédric DUCLOS, MD, Contact
Recruiting